Company intelligence / Profile preview

Rapport Therapeutics

boston_headquarters_cited_in_press_releases[5][10], multiple_locations_suggested_by_press_releases, United Statesrapportrx.com ↗
Ownership
Public · RAPP
Development stage
Other
01

Overview

  • Lead candidate RAP-219 shows neuroanatomical specificity through TARPγ8 targeting[5][10]
  • Phase1 PET/MAD-2 trials demonstrated target engagement and favorable tolerability in healthy subjects[5][10]
  • Phase2a epilepsy trial on track for Q3'25 topline results[5][6]
Therapeutic areas
PsychiatryNeurology
Modalities
small molecules
Industry
Biotech
02

Drug pipeline

5 assets

RAP-219

3

4 more assets in the full pipeline.

03

Financials

Market cap
$1.1B
Total revenue
$0
Enterprise value
$752.4M

Beyond the preview

Go deeper on Rapport Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapport Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call